Amorfix recruits ALS leader, Joseph Beckman, Ph.D. to join Scientific Advisory Board
Amorfix Life Sciences announced that Joseph Beckman, Ph.D., will join the Company's Scientific Advisory Board. Dr. Beckman is an expert in amyotrophic lateral sclerosis (ALS) disease and the role of superoxide dismutase-1 (SOD1) in this disease.
Dr. Beckman holds the Ava Helen Pauling Chair in the Linus Pauling Institute, is a Professor in the Department of Biochemistry and Biophysics and serves as the Director, Environmental Health Sciences Center at Oregon State University. He is an active contributor to a number of professional associations and has served as a regular reviewer for the National Institutes of Health and on a number of editorial boards of scientific journals.
Most read news
Topics
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs

Coupled Proteins - How human cells react to external signals and further process them

'Trojan horse' anticancer drug disguises itself as fat - Promising system delivers chemo drug straight into tumors with fewer side effects
Oncothyreon announces issuance of patent for PX-867
Hypocapnia
UCB strengthens strategic alliance with WILEX - UCB's position as a strategic investor now represents 18% of WILEX shares
Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN
